acut
respiratori
tract
infect
ari
among
common
reason
primari
care
world
health
organ
rank
ari
fourth
major
killer
cardiovascular
diseas
gener
infect
parasit
diseas
ari
caus
million
death
global
burden
especi
high
children
ari
respons
ari
lead
sever
complic
requir
hospit
fatal
outcom
virus
common
etiolog
ari
includ
rhinoviru
rhv
respiratori
syncyti
viru
rsv
influenza
ifn
parainfluenza
viru
piv
coronaviru
cov
human
metapneumoviru
hmpv
enterovirus
ev
adenoviru
adv
human
bocaviru
hbov
virus
pose
signific
health
burden
nair
et
al
estim
death
children
year
attribut
influenzaassoci
lower
respiratori
tract
infect
lri
vast
major
occur
develop
rsv
estim
caus
million
lri
episod
children
five
million
sever
caus
addit
health
burden
viral
respiratori
tract
infect
rti
econom
impact
also
high
account
health
care
cost
direct
cost
loss
product
indirect
cost
studi
fendrik
et
al
estim
total
econom
impact
noninfluenzarel
viral
rti
unit
state
billion
advanc
achiev
develop
antivir
drug
alreadi
approv
respiratori
virus
allow
target
therapi
viral
possibl
call
better
faster
diagnosi
etiolog
agent
ari
patient
benefit
full
potenti
furthermor
ari
associ
greatest
amount
excess
use
antibiot
led
unpreced
increas
antimicrobi
drug
resist
therefor
proper
time
diagnosi
viral
infect
help
reduc
unnecessari
antibiot
lebanon
studi
investig
viral
etiolog
ari
scarc
studi
determin
viral
etiolog
among
ari
patient
tertiari
care
hospit
serv
ethnic
socioeconom
divers
patient
popul
infant
children
younger
year
age
symptom
ari
diseas
present
emerg
depart
depart
pediatr
american
univers
beirut
medic
center
aubmc
beirut
lebanon
prospect
recruit
septemb
februari
ari
defin
acut
infect
upper
lower
respiratori
airway
recruit
patient
one
follow
symptom
fever
cough
sore
throat
rhinorrhea
headach
conjunct
wheez
dyspnea
vomit
medic
histori
demograph
data
obtain
patient
medic
record
respiratori
sampl
collect
store
viral
assess
studi
approv
institut
review
board
irb
aubmc
written
inform
consent
obtain
parent
nucleic
acid
extract
clinic
specimen
use
qiaamp
minelut
viru
spin
kit
qiagen
accord
manufactur
protocol
aliquot
specimen
use
nucleic
extract
specimen
analyz
resplex
ii
panel
qiagen
use
manufactur
protocol
resplex
ii
panel
detect
viral
target
rsva
rsvb
infa
infb
hmpv
cvev
coxsackieviru
echoviru
rhv
briefli
specimen
ad
revers
transcriptionpcr
resplex
ii
master
mix
includ
suppli
primer
target
detect
mix
portion
amplif
product
resplex
ii
bead
hybrid
buffer
min
streptavidinphycoerythrin
conjug
ad
mixtur
incub
min
addit
stop
buffer
sampl
analyz
luminex
biorad
bioplex
system
biorad
laboratori
use
biorad
bioplex
manag
softwar
cutoff
valu
target
determin
previous
describ
lia
et
data
check
complet
respons
code
enter
statist
packag
social
scienc
spss
softwar
version
window
later
use
statist
descript
statist
present
summar
studi
variabl
interest
count
percentag
categor
variabl
median
interquartil
rang
iqr
continu
one
chisquar
test
use
calcul
associ
two
categor
variabl
pearson
chisquar
analysi
bonferroniholm
pvalu
correct
use
multipl
comparison
assess
infect
enhanc
correl
univari
multivari
logist
regress
analys
appli
determin
factor
associ
rhinorrhea
regress
model
rhinorrhea
use
depend
variabl
odd
ratio
respect
confid
interv
calcul
analysi
done
pvalu
less
consid
statist
signific
total
specimen
collect
children
present
symptom
ari
septemb
februari
tabl
sociodemograph
characterist
studi
patient
present
tabl
overal
studi
consist
male
femal
patient
median
age
iqr
year
seventyfour
patient
children
one
year
age
year
old
year
old
year
old
sixtyseven
children
underli
diseas
asthma
immunedefici
allerg
rhiniti
cystic
fibrosi
time
diagnosi
patient
receiv
chemotherapi
receiv
antibiot
sampl
screen
viru
target
includ
resplexii
respiratori
panel
ari
episod
confirm
viral
etiolog
posit
least
one
viru
target
test
tabl
major
viral
ari
episod
observ
children
age
chisquar
p
figur
show
frequenc
virus
detect
studi
popul
overal
virus
detect
rhinoviru
rhv
common
viru
detect
patient
follow
coxsacki
viru
echoviru
cvev
detect
one
target
panel
patient
parainfluenza
virus
piv
type
respiratori
syncyti
viru
rsv
type
b
coinfect
one
viru
detect
patient
figur
signific
major
chisquar
pvalu
coinfect
occur
children
six
year
age
frequent
viral
coinfect
involv
two
virus
case
tripl
infect
four
virus
detect
one
case
five
virus
almost
half
case
rhinoviru
posit
least
anoth
viru
panel
cvev
posit
case
also
high
rate
coinfect
moreov
hmpv
infb
detect
sampl
coinfect
tabl
summar
correl
differ
virus
among
patient
sever
correl
enhanc
infect
evid
analysi
note
rhv
frequent
detect
viru
coinfect
significantli
associ
rsvb
infb
hmpv
cvev
next
analyz
correl
viral
etiolog
coinfect
underli
condit
tabl
simplifi
analysi
treat
subtyp
genotyp
viru
singl
group
eg
rsv
rsva
rsvb
etc
underli
condit
receiv
chemotherapi
cours
antibiot
found
risk
factor
viral
etiolog
coinfect
tabl
addit
investig
season
variat
virus
rhinoviru
infect
detect
throughout
year
howev
peak
rate
occur
main
raini
month
novemb
decemb
like
coxsackieechoviru
rsv
hand
influenza
viru
infect
peak
fall
septemb
octob
figur
term
clinic
symptom
fever
cough
rhinorrhea
major
symptom
observ
patient
infect
one
respiratori
viru
tabl
chisquar
analysi
reveal
signific
correl
rhinorrhea
inf
cvev
rhv
coinfect
tabl
bivari
logist
regress
perform
determin
risk
associ
infect
analysi
reveal
rhv
cvev
infect
patient
patient
infect
one
viru
like
rhinorrhea
rhv
ci
cvev
ci
coinfect
ci
multivari
logist
regress
model
use
examin
correl
rhinorrhea
studi
patient
variabl
put
model
order
strength
correl
rhinorrhea
per
bivari
analysi
effect
variabl
model
assess
variabl
kept
significantli
contribut
better
fit
model
final
model
includ
follow
variabl
rhv
cvev
result
multivari
model
show
cvev
independ
associ
rhinorrhea
ci
cvev
infect
patient
time
like
rhinorrhea
compar
nonecvev
patient
control
rhv
unlik
bivari
analysi
rhv
significantli
associ
rhinorrhea
ci
rhv
infect
patient
time
like
rhinorrhea
compar
nonerhv
patient
control
cvev
howev
statist
signific
demonstr
viral
infect
respons
least
half
ari
children
lebanon
rhinoviru
infect
common
etiolog
ari
consist
studi
lebanon
neighbor
jordan
egypt
rhinoviru
incid
second
rsv
popul
captur
studi
younger
includ
overal
viral
ari
incid
studi
lower
recent
report
finiano
et
al
studi
target
children
howev
finiano
et
al
screen
specimen
viral
target
includ
analysi
studi
test
hcov
adv
ev
hbov
collect
account
viral
ari
studi
finiano
et
al
coinfect
rate
studi
higher
previous
report
lebanon
qatar
egypt
incongru
could
cvev
frequent
detect
virus
studi
screen
previou
studi
cvev
infect
commonli
report
studi
investig
respiratori
infect
studi
cvev
infect
constitut
viral
ari
case
independ
associ
rhinorrhea
incid
much
higher
report
countri
recent
studi
latin
america
report
cvev
associ
ari
central
america
cvev
even
much
lower
low
preval
cvev
region
might
discourag
test
given
high
preval
cvev
lebanon
recommend
test
enterovirus
includ
cvev
coinfect
found
common
younger
children
lebanon
similar
previou
studi
done
mexican
children
show
major
coinfect
occur
children
month
younger
children
like
prone
infect
due
lack
still
weak
immun
respiratori
virus
effect
coinfect
diseas
outcom
well
patient
coinfect
pandem
influenza
rhinoviru
tend
milder
clinic
sever
compar
nonrhinoviru
coinfect
patient
coinfect
hmpv
rsv
prone
higher
risk
sever
addit
preval
sever
obstruct
airway
diseas
higher
patient
studi
coinfect
associ
higher
risk
rhinorrhea
sever
symptom
like
dyspnea
contrast
studi
show
correl
coinfect
statu
clinic
complex
viral
coinfect
larg
number
respiratori
virus
involv
make
challeng
studi
effect
coinfect
diseas
outcom
clinic
set
therefor
need
develop
vitro
vivo
model
allow
better
understand
coinfect
exampl
dual
infect
inf
shown
suppress
rsv
growth
suppress
rsv
inf
suggest
due
competit
protein
synthesi
bud
cell
surfac
studi
warrant
investig
interact
among
respiratori
virus
coinfect
effect
host
studi
coupl
limit
first
screen
hbov
hcov
includ
resplex
ii
kit
thu
preval
viral
ari
expect
higher
anoth
limit
inabl
rule
bacteri
etiolog
test
current
studi
conclus
viral
etiolog
contribut
larg
proport
ari
mani
involv
one
viral
agent
